Ensign Peak Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Ensign Peak Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-67,332	Closed	-$331K	–	1741
2024 Q1	$331K	Buy	67,332 +16,982	+34%	+$101K	﹤0.01%	1680
2023 Q4	$443K	Buy	50,350 +13,350	+36%	+$109K	﹤0.01%	1679
2023 Q3	$424K	Hold	37,000	–	–	﹤0.01%	1635
2023 Q2	$936K	Hold	37,000	–	–	﹤0.01%	1315
2023 Q1	$1.19M	Hold	37,000	–	–	﹤0.01%	1099
2022 Q4	$683K	Buy	37,000 +15,200	+70%	+$348K	﹤0.01%	1475
2022 Q3	$589K	Hold	21,800	–	–	﹤0.01%	1370
2022 Q2	$301K	Hold	21,800	–	–	﹤0.01%	1684
2022 Q1	$425K	Buy	21,800 +8,570	+65%	+$130K	﹤0.01%	1620
2021 Q4	$216K	Buy	+13,230	New	+$221K	﹤0.01%	1910

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's RVNC Position: Q2 2024 in Review

Ensign Peak Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 67,332 shares — an estimated $331K sold.

Ensign Peak Advisors first reported a position in RVNC in Q4 2021 and held it in 10 quarters. The position peaked at $1.19M in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Ensign Peak Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Ensign Peak Advisors sold 67,332 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $331K.
Ensign Peak Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 10 quarters.
Ensign Peak Advisors's Revance Therapeutics, Inc. position peaked at $1.19M in Q1 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.